Warner Chilcott PLC has filed an abbreviated new drug application with the FDA for an AB rateable form of terazosin hydrochloride capsules, said to be a bioequivalent of Abbott Laboratories' Hytrin alpha blocker.
COPYRIGHT 1998 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group